BRCA2 and breast cancer: None of the PRS showed significant associations with ER-negative contralateral breast cancer for BRCA2 heterozygotes, but the ER-negative PRS313 exhibited the largest HR estimate, HR per SD = 1.10, 95% CI (0.91–1.32), p value = 0.346.